Response by Watts et al to Letter Regarding Article, "Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism"

Circulation. 2017 Jul 4;136(1):120-121. doi: 10.1161/CIRCULATIONAHA.117.028790.

Authors

Gerald F Watts¹, Dick C Chan¹, Ransi Somaratne¹, Scott M Wasserman¹, Marc S Sabatine¹

Affiliation

¹ From Department of Cardiology, Lipid Disorders Clinic, Royal Perth Hospital, Perth (G.F.W.); School of Medicine and Pharmacology, University of Western Australia, Perth (G.F.W., D.C.C.); Amgen Inc., Thousand Oaks, CA (R.S., S.M.W.); and TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.S.S.).

PMID: 28674100
DOI: 10.1161/CIRCULATIONAHA.117.028790

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal*
Antibodies, Monoclonal, Humanized
Anticholesteremic Agents
Atorvastatin*
Lipoproteins

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Anticholesteremic Agents
Lipoproteins
Atorvastatin
evolocumab